Inventor · disambiguated record
Peter H. Fuller
Also filed as: FULLER PETER · FULLER PETER H
16 granted patents·7 pending applications·19 citations·filing 2014–2023
88Inventor score
Files withMERCK SHARP & DOHME12MERCK SHARP & DOHME LLC8DIMAURO ERIN F1FISCHER CHRISTIAN1INTERVET INC1
Top patents by PatentIndex Score
23 records- 0185US10766883B2Aminopyrazoles as janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2017·Granted Sep 8, 2020·3 cites·20 claims
- 0285US10287272B2Substituted indazole compounds as RORgammaT inhibitors and uses thereofMERCK SHARP & DOHME·Filed 2016·Granted May 14, 2019·3 cites·30 claims
- 0382US10875847B2Aminopyrazoles as selective janus kinase inhibitorsINTERVET INC·Filed 2017·Granted Dec 29, 2020·2 cites·18 claims
- 0478US12030872B2N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereofMERCK SHARP & DOHME LLC·Filed 2019·Granted Jul 9, 2024·2 cites·15 claims
- 0578US11161854B2Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereofMERCK SHARP & DOHME·Filed 2018·Granted Nov 2, 2021·2 cites·10 claims
- 0678US10221142B2Substituted pyrazole compounds as RORgammaT inhibitors and uses thereofMERCK SHARP & DOHME·Filed 2016·Granted Mar 5, 2019·3 cites·29 claims
- 0771US10344000B2Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereofMERCK SHARP & DOHME·Filed 2016·Granted Jul 9, 2019·1 cites·23 claims
- 0871US9725445B2Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted Aug 8, 2017·2 cites·17 claims
- 0967US10689369B2Substituted indazole compounds as RORgammaT inhibitors and uses thereofMERCK SHARP & DOHME·Filed 2019·Granted Jun 23, 2020·0 cites·24 claims
- 1066US9957264B2Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted May 1, 2018·1 cites·9 claims
- 1157US2025313575A1Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereofMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 1256US2024208986A1Phenyl azepines as ripk1 inhibitors and methods of use thereofMERCK SHARP & DOHME LLC·Filed 2022·Application pending·0 cites
- 1356US2024228506A1Ripk1 inhibitors and methods of useDIMAURO ERIN F·Filed 2022·Application pending·0 cites
- 1455US2024308980A1Heteroaryl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereofMERCK SHARP & DOHME LLC·Filed 2022·Application pending·0 cites
- 1554US2024398784A1C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereofMERCK SHARP & DOHME LLC·Filed 2022·Application pending·0 cites
- 1652US2023399341A17-phenyl substituted 2-aminoquinazoline inhibitors of hpk1MERCK SHARP & DOHME LLC·Filed 2021·Application pending·0 cites
- 1749US2023406864A17-azole substituted 2-aminoquinazoline inhibitors of hpk1MERCK SHARP & DOHME LLC·Filed 2021·Application pending·0 cites
- 1848US12319671B21-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereofMERCK SHARP & DOHME LLC·Filed 2020·Granted Jun 3, 2025·0 cites·16 claims
- 1946US11174248B2Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereofMERCK SHARP & DOHME·Filed 2018·Granted Nov 16, 2021·0 cites·11 claims
- 2043US10059705B2Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted Aug 28, 2018·0 cites·7 claims
- 2143US9957265B2N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted May 1, 2018·0 cites·11 claims
- 2239US10072025B2Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted Sep 11, 2018·0 cites·17 claims
- 2334US10442819B2Tricyclic compounds as inhibitors of mutant IDH enzymesFISCHER CHRISTIAN·Filed 2015·Granted Oct 15, 2019·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Peter H. Fuller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →